Radiopharm Theranostics has received US Food and Drug Administration approval to begin a Phase 1 imaging trial in ambulatory patients with pancreatic cancer.
The first subject is expected to be dosed at Montefiore Einstein Cancer Center in New York.
Pancreatic cancer presents a high unmet medical need with current imaging options having several limitations.
Paul Hopper, Executive Chairman and Riccardo Canevari, CEO & Managing Director, are both looking forward to positive outcomes from the trial.
Dr. Lionel S. Zuckier, MD, MBA, also expressed his support for improved imaging agents for optimized patient diagnosis and management.
Radiopharm Theranostics is working with TRIMT GmbH to develop radiopharmaceuticals including Ga68-Integrin (RAD301).
Following the announcement, shares of Radiopharm Theranostics (ASX:RAD) were unchanged at $0.10.